These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 16411336)

  • 1. Metabolic syndrome and schizophrenia.
    Reynolds GP
    Br J Psychiatry; 2006 Jan; 188():86; author reply 86-7. PubMed ID: 16411336
    [No Abstract]   [Full Text] [Related]  

  • 2. Six months' course and outcome of metabolic abnormalities in a cohort of patients with schizophrenia in rural India.
    Bijjal S; Ganesh S; Rawat VS; Agarwal V; Shanivaram Reddy K; Renuka Devi NR; Kumar CN; Christopher R; Thirthalli J
    Schizophr Res; 2018 Nov; 201():415-416. PubMed ID: 29880456
    [No Abstract]   [Full Text] [Related]  

  • 3. Antipsychotic drugs and metabolic syndrome--can we prevent it?
    Reis AF
    Braz J Psychiatry; 2007 Mar; 29(1):9-10. PubMed ID: 17435920
    [No Abstract]   [Full Text] [Related]  

  • 4. Metabolic syndrome associated with schizophrenia and atypical antipsychotics.
    Hasnain M; Fredrickson SK; Vieweg WV; Pandurangi AK
    Curr Diab Rep; 2010 Jun; 10(3):209-16. PubMed ID: 20425584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic syndrome in patients with schizophrenia: CATIE results.
    Narasimhan M; Masand P
    Curr Psychiatry Rep; 2006 Jun; 8(3):213-4. PubMed ID: 19817071
    [No Abstract]   [Full Text] [Related]  

  • 6. [Efficacy and tolerance of antipsychotic agents: what are the current issues?].
    Canceil O
    Encephale; 2006 Oct; 32(5 Pt 4):S927-8. PubMed ID: 17119510
    [No Abstract]   [Full Text] [Related]  

  • 7. Bipolar disorder, schizophrenia, and metabolic syndrome.
    Bartoli F; Carrà G; Crocamo C; Carretta D; Clerici M
    Am J Psychiatry; 2013 Aug; 170(8):927-8. PubMed ID: 23903338
    [No Abstract]   [Full Text] [Related]  

  • 8. Metabolic syndrome in schizophrenia - who is more to blame: FGA polypharmacy or clozapine monotherapy?
    Softic R; Sutovic A; Avdibegovic E; Osmanović E; Bećirović E; Hajdukov MM
    Psychiatr Danub; 2015 Dec; 27(4):378-84. PubMed ID: 26609650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiometabolic Risks in Schizophrenia and Directions for Intervention, 1: Magnitude and Moderators of the Problem.
    Andrade C
    J Clin Psychiatry; 2016 Jul; 77(7):e844-7. PubMed ID: 27464317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second generation antipsychotic-induced mitochondrial alterations: Implications for increased risk of metabolic syndrome in patients with schizophrenia.
    Scaini G; Quevedo J; Velligan D; Roberts DL; Raventos H; Walss-Bass C
    Eur Neuropsychopharmacol; 2018 Mar; 28(3):369-380. PubMed ID: 29449054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physical Health and Drug Safety in Individuals with Schizophrenia.
    Pringsheim T; Kelly M; Urness D; Teehan M; Ismail Z; Gardner D
    Can J Psychiatry; 2017 Sep; 62(9):673-683. PubMed ID: 28718324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats.
    Horska K; Ruda-Kucerova J; Drazanova E; Karpisek M; Demlova R; Kasparek T; Kotolova H
    Neuropharmacology; 2017 Sep; 123():148-158. PubMed ID: 28595931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic monitoring and management among clozapine users.
    Tso G; Kumar P; Jayasooriya T; Kisely S; Siskind D
    Australas Psychiatry; 2017 Feb; 25(1):48-52. PubMed ID: 27590080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two Hypotheses on the High Incidence of Dementia in Psychotic Disorders.
    Jonas K; Abi-Dargham A; Kotov R
    JAMA Psychiatry; 2021 Dec; 78(12):1305-1306. PubMed ID: 34524413
    [No Abstract]   [Full Text] [Related]  

  • 15. Relationships between IGF-1, schizophrenia, and treatment of metabolic syndrome.
    Demirel A; Demirel OF; Emül M; Duran A; Uğur M
    Compr Psychiatry; 2014 Aug; 55(6):1391-7. PubMed ID: 24850069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between SCAP and SREBF1 gene polymorphisms and metabolic syndrome in schizophrenia patients treated with atypical antipsychotics.
    Yang L; Chen J; Li Y; Wang Y; Liang S; Shi Y; Shi S; Xu Y
    World J Biol Psychiatry; 2016 Sep; 17(6):467-74. PubMed ID: 26982812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clozapine use and sedentary lifestyle as determinants of metabolic syndrome in outpatients with schizophrenia.
    Eskelinen S; Sailas E; Joutsenniemi K; Holi M; Suvisaari J
    Nord J Psychiatry; 2015 Jul; 69(5):339-45. PubMed ID: 25981178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin Resistance in Schizophrenia.
    Guest PC
    Adv Exp Med Biol; 2019; 1134():1-16. PubMed ID: 30919329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exercise, diet and educational interventions for metabolic syndrome in persons with schizophrenia: A systematic review.
    Gurusamy J; Gandhi S; Damodharan D; Ganesan V; Palaniappan M
    Asian J Psychiatr; 2018 Aug; 36():73-85. PubMed ID: 29990631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between antipsychotic-induced metabolic side-effects and clinical improvement: a review on the evidence for metabolic threshold: author's response.
    Sharma E; Rao NP; Venkatasubramanian G
    Asian J Psychiatr; 2014 Oct; 11():76. PubMed ID: 25453703
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.